Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
Status:
Terminated
Trial end date:
2019-05-16
Target enrollment:
Participant gender:
Summary
This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of
avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients
must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian
(EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for
platinum-based chemotherapy.
The primary purpose of the study is to demonstrate if avelumab given as single agent in the
maintenance setting following frontline chemotherapy or in combination with
carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by
observation in this population of newly diagnosed ovarian cancer patients.